A Phase I Clinical Trial to Evaluate CU-10101 Unguent
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
- Target Recruit Count
- 64
- Registration Number
- NCT06744569
- Locations
- 🇨🇳
Shanghai Skin Disease Hospital, Shanghai, Shanghai, China
A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type a for Injection (CU-20101)
Phase 3
Active, not recruiting
- Conditions
- Glabellar Frown Lines
- Interventions
- Drug: CU-20101 treatment for Moderate to Severe Glabellar Striae
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
- Target Recruit Count
- 554
- Registration Number
- NCT06585696
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
A Phase 2 Clinical Study of CU-20401
Phase 2
Completed
- Conditions
- Efficacy and Safety
- Interventions
- Drug: Subcutaneous injection of CU-20401
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
- Target Recruit Count
- 108
- Registration Number
- NCT06194188
- Locations
- 🇨🇳
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Efficacy and Safety of Lidocaine and Tetracaine Cream for Facial Laser Aesthetics in Chinese Adults
- First Posted Date
- 2023-03-31
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
- Target Recruit Count
- 286
- Registration Number
- NCT05793892
- Locations
- 🇨🇳
Shanghai Ninth People Hospital,Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
🇨🇳Beijing Hospital, Beijing, China
🇨🇳Beijing Tsinghua Changgung Hospital, Beijing, China
A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
- Target Recruit Count
- 62
- Registration Number
- NCT05380427
- Locations
- 🇨🇳
The Second Affiliated Hospital Zhejiang University School of Medicine, Zhejiang, Hangzhou, China
A Clinical Study to Evaluate the Safety, Pharmacokinetic Profile and Efficacy of CU-20401
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
- Target Recruit Count
- 48
- Registration Number
- NCT05195541
- Locations
- 🇨🇳
Shanghai Changhai Hospital, Shanghai, Shanghai, China
A Phase 1 Clinical Study of CU-20401 in Chinese Healthy Population
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: injection ，CU-20401Drug: injection ，placebo
- First Posted Date
- 2021-12-30
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
- Target Recruit Count
- 48
- Registration Number
- NCT05173883
- Locations
- 🇨🇳
Shanghai Xuhui Hospital, Shanghai, Shanghai, China
A Phase 3 Clinical Study Patients With Androgenetic Alopecia (AGA)
Phase 3
Completed
- Conditions
- AGA
- Interventions
- Drug: CU-40102 Spray
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
- Target Recruit Count
- 270
- Registration Number
- NCT05135468
- Locations
- 🇨🇳
Peking University People Hosptial, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath